Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been assigned an average rating of “Moderate Buy” from the twenty-five research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twenty-three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $212.50.

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. lowered their price objective on Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research report on Monday, June 8th. Raymond James Financial assumed coverage on Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price objective for the company. Bank of America increased their price objective on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Royal Bank Of Canada lowered their price target on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Jefferies Financial Group began coverage on Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 price target for the company.

Insmed Trading Down 0.4%

Shares of Insmed stock opened at $97.46 on Tuesday. The firm has a market capitalization of $21.12 billion, a price-to-earnings ratio of -16.95 and a beta of 0.79. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The stock has a 50 day moving average of $123.25 and a 200 day moving average of $150.13.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.42) earnings per share. As a group, research analysts predict that Insmed will post -2.54 earnings per share for the current year.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 160,482 shares of company stock valued at $24,438,193. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INSM. CIBC Private Wealth Group LLC boosted its position in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Insmed during the fourth quarter worth $27,000. GraniteShares Advisors LLC purchased a new position in shares of Insmed during the fourth quarter worth $30,000. Reflection Asset Management acquired a new stake in shares of Insmed in the fourth quarter valued at $30,000. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Insmed in the fourth quarter valued at $32,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.